From Phase 3 To Commercialization: What Sterile Injectable Sponsors Need To Know

An Executive Q&A with Ryan Downey, Vice President of Technical Operations at August Bioservices

Navigating late-stage sterile injectable manufacturing requires a deliberate strategy that extends far beyond securing line time. As programs advance toward Phase 3 and commercialization, priorities shift from initial drug characterization to process robustness, validation, and long-term scalability. Escalating fill-finish capacity demands—fueled by high-volume therapeutics like GLP-1s—alongside tightened Annex 1 regulatory expectations and supply chain constraints, make selecting the right manufacturing partner critical. Integrating analytical support, device functionality testing, and single-use system strategies under one roof mitigates handoff risks and protects critical process knowledge.

Discover how aligning validated infrastructure, U.S.-based operations, and deep technical expertise early in development streamlines regulatory approval and safeguards commercial product delivery.